What is NCT04512345 studying with aminolevulinic acid hydrochloride?
NCT04512345 is a clinical trial registered to evaluate aminolevulinic acid hydrochloride (ALA HCl). Aminolevulinic acid hydrochloride is used as a “photosensitizer” that can accumulate in targeted tissues and fluoresce under specific light, supporting procedures that rely on light-based detection or visualization. The registry entry for NCT04512345 lists the trial design and condition being studied, along with eligibility criteria and outcome measures.
Where can I find the trial details (condition, phase, status, locations)?
For the most reliable, up-to-date trial information—such as:
- study phase (if listed),
- recruiting status,
- study sites,
- primary and secondary outcomes,
- inclusion/exclusion criteria,
- and dates (start/completion),
you can look up the study directly using its ClinicalTrials.gov identifier: NCT04512345.
What does “aminolevulinic acid hydrochloride” mean in these kinds of trials?
In ALA-based trials, the drug is typically administered before a procedure. During the procedure, light exposure can trigger fluorescence that helps clinicians identify abnormal tissue or treatment targets more clearly than visual inspection alone. The specific clinical use depends on the condition and protocol in that particular NCT number.
How long does the trial take, and when do results typically appear?
Trial timelines vary by indication, recruitment speed, and follow-up requirements. ClinicalTrials.gov entries usually show planned and actual milestones (completion dates), but result postings depend on whether the sponsor submits results to the registry and on publication timing.
Are there related trials or competing approaches?
If your goal is to compare ALA protocols against other fluorescence agents or imaging strategies (or to find nearby trials with similar inclusion criteria), the ClinicalTrials.gov search around NCT04512345 (and related drug name searches for aminolevulinic acid hydrochloride) is the best way to identify overlapping studies.
DrugPatentWatch.com angle: is there a patent or exclusivity issue for ALA HCl?
If you’re checking the commercial or patent landscape for aminolevulinic acid hydrochloride, DrugPatentWatch.com can be a useful secondary source for patent/exclusivity context. However, patent data won’t replace the trial-specific details that come from the NCT record.
If you share what you’re trying to learn (e.g., the condition, whether it’s recruiting, dosing, or the primary endpoint), I can help interpret what the NCT04512345 entry is saying in plain language. Also, if you paste the trial’s “Brief Summary” or “Conditions” text from ClinicalTrials.gov, I can give a tighter readout focused on that exact study.
Sources:
1. DrugPatentWatch.com